

## Press Release

### CureVac strengthens supervisory board to support global growth opportunities and mRNA product expansion

**TÜBINGEN, Germany, March 18, 2016** – CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced the appointment of three seasoned industry experts to its supervisory board. The new advisors are:

- **Ralf Clemens, M.D., Ph.D.**, a senior executive in the vaccine industry who has held various senior scientific and business positions, including at GSK Biologicals and Novartis. He chairs CureVac's scientific advisory board.
- **Baron Jean Stéphenne, M.Sc., M.B.A.**, who steered GSK Biologicals through very innovative developments and a series of acquisitions to create one of the leading global vaccine companies. He acts as representative of the Bill & Melinda Gates Foundation.
- **Chris Tanner, Ph.D.**, a finance professional who was responsible for a number of initial public offerings during his tenure as head of corporate finance and capital markets at UBS in Zurich. Since 2006, he has been Chief Financial Officer of Cosmo Pharmaceuticals S.A., for which he led the IPO process.

These advisors join existing supervisory board members Friedrich von Bohlen, Ph.D. (Chairman), Prof. Wolfgang Hartwig, Ph.D., and Mathias Hothum, Ph.D.

Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, stated, "We are pleased to welcome these highly-respected experts to CureVac's supervisory board as we continue to advance our mRNA-based medicines to address significant therapeutic needs and global market opportunities."

Friedrich von Bohlen, Ph.D., Chairman of CureVac's supervisory board, said, "We are very much looking forward to establishing a close working relationship with our new members. Benefitting from their extensive pharmaceutical industry experience, we feel well-positioned to continue our successful course in the development of mRNA-based medicines for numerous disease areas and indications."

CureVac's full supervisory board can be found here:  
<http://www.curevac.com/company/supervisory-board/>

#### About CureVac AG

Founded in 2000 as a spin-off from the University of Tübingen in Germany, CureVac is a technology leader in the development of drugs that are based on the molecule Messenger RNA (mRNA). The company has more than 15 years of expertise in handling and optimizing this versatile molecule for medical purposes and has the most advanced product pipeline and IP portfolio in the industry.

The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.

Since its inception, CureVac has received approximately \$330 million (€300 million) in equity investments. CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, the Bill & Melinda Gates Foundation and IAVI.

In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2016 CureVac will start the construction of an industrial scale production facility.

For more information, please visit [www.curevac.com](http://www.curevac.com).

\*\*\*

### **Media Contacts**

Verena Lauterbach, Senior Manager Communications  
CureVac AG, Tübingen, Germany  
T: +49 (0) 7071 9883 1756  
[communications@curevac.com](mailto:communications@curevac.com)

Andrew Mielach, Vice President  
Tiberend Strategic Advisors, New York  
T: +1 212 375 2694  
[amielach@tiberend.com](mailto:amielach@tiberend.com)

Rachel Hunter, Account Director  
Brunswick Group, New York  
T: +1 (0) 213 333 3810  
[rhunter@brunswickgroup.com](mailto:rhunter@brunswickgroup.com)